Chapter 38 — Antiparasitic Drugs — Module 4 — Ectoparasiticides and Special Populations
1. A clinic in a high-resistance region maintains a short list of head lice agents that remain reliable when knockdown resistance (kdr, a sodium-channel mutation) is widespread: malathion, spinosad, and benzyl alcohol. What single unifying principle explains why all three retain activity against kdr-resistant lice?
A) All three are pyrethroids that bind the sodium channel more tightly than permethrin does
B) All three are dosed orally, bypassing the topical resistance entirely
C) None of the three relies on the voltage-gated sodium channel for its lethal effect, so a sodium-channel mutation gives the louse no protection against any of them
D) All three chemically reverse the kdr mutation, restoring a drug-sensitive channel
E) All three are ovicidal, and kdr affects only adult lice and never the eggs
ANSWER: C
Rationale:
The defining feature of the three reliable agents is that none of them kills through the voltage-gated sodium channel, which is the target altered by the kdr mutation. Malathion inhibits acetylcholinesterase, spinosad activates nicotinic acetylcholine receptors and glutamate-gated chloride channels, and benzyl alcohol physically asphyxiates the louse by blocking its spiracles. Because the killing mechanism lies entirely off the mutated channel, a sodium-channel mutation cannot protect the louse from any of them. This is the integrating principle behind rational agent choice in a kdr-prevalent setting.
Option A: Option A is incorrect: none of the three is a pyrethroid; if they bound the sodium channel they would share the same kdr cross-resistance as permethrin.
Option B: Option B is incorrect: malathion, spinosad, and benzyl alcohol are all topical agents, so an oral route is not what spares them from resistance.
Option D: Option D is incorrect: none of these drugs reverses or repairs the genetic kdr mutation; they simply act on different targets.
Option E: Option E is incorrect: ovicidal activity varies among them and is not the reason they overcome kdr; benzyl alcohol works physically, and kdr is not an egg-versus-adult distinction.
2. Permethrin and benzyl alcohol both treat head lice, yet only one of them faces a meaningful resistance problem. Comparing their mechanisms, which statement correctly relates mechanism to resistance potential?
A) Permethrin acts on a specific molecular target (the sodium channel), so a target-site mutation can defeat it, whereas benzyl alcohol kills by a physical action (blocking the breathing spiracles), which offers no molecular target for the louse to mutate and therefore no recognized resistance
B) Both act on the sodium channel, so both are equally vulnerable to kdr resistance
C) Benzyl alcohol acts on a specific enzyme and is therefore more prone to resistance than permethrin
D) Permethrin works physically and benzyl alcohol works on a receptor, so permethrin is the resistance-proof agent
E) Neither has any resistance risk because both are physical agents
ANSWER: A
Rationale:
The comparison turns on target type. Permethrin binds a specific molecular target, the voltage-gated sodium channel; a point mutation in that channel (kdr) reduces binding and confers resistance. Benzyl alcohol kills mechanically, by blocking the spiracles and asphyxiating the louse, so there is no discrete binding site for the louse to alter, and no resistance mechanism is recognized. Linking mechanism type to resistance potential is the conceptual point: molecular-target drugs are mutable targets; physical mechanisms are not.
Option B: Option B is incorrect: only permethrin acts on the sodium channel; benzyl alcohol does not, so they are not equally vulnerable to kdr.
Option C: Option C is incorrect: benzyl alcohol does not act on a specific enzyme; its physical mechanism makes it less, not more, prone to resistance.
Option D: Option D is incorrect: the roles are reversed; permethrin is the target-based agent and benzyl alcohol is the physical one, so permethrin is the resistance-prone agent.
Option E: Option E is incorrect: permethrin is not a physical agent and does carry resistance risk, so the claim that neither has resistance risk is wrong.
3. A patient with crusted scabies fails a standard course of topical permethrin alone. Integrating what is known about this disease, why does monotherapy of any single kind tend to fail, and what does the successful regimen address?
A) The mite in crusted scabies is a different species unaffected by any scabicide
B) Monotherapy fails only because the patient is non-adherent; a single agent applied correctly always cures crusted scabies
C) The crust enhances drug penetration, so the problem is overdosing rather than underdosing
D) The thick hyperkeratotic crust blocks topical penetration and shelters an enormous mite burden, so the successful regimen combines a systemic agent (oral ivermectin, which reaches mites the cream cannot) with topical permethrin and a keratolytic to dissolve the crust, attacking the problem from inside, outside, and by removing the barrier
E) Oral ivermectin alone reliably cures crusted scabies, so no topical therapy or crust removal is ever needed
ANSWER: D
Rationale:
Crusted scabies fails single-agent therapy for two linked reasons: the thick hyperkeratotic crust physically prevents topical drug from reaching the mites, and the mite burden is enormous (millions rather than the 10 to 15 of common scabies). The effective regimen therefore works on three fronts at once: a systemic agent (repeated oral ivermectin) reaches mites the cream cannot; topical permethrin treats the surface; and a keratolytic such as salicylic acid breaks down the crust so the topical drug can finally penetrate. The integration of barrier, burden, and route is the conceptual core.
Option A: Option A is incorrect: crusted scabies is caused by the same Sarcoptes scabiei mite, not a drug-immune different species; the failure is about penetration and burden.
Option B: Option B is incorrect: even with perfect adherence, a single topical agent fails because of the crust barrier and mite burden, so non-adherence is not the whole explanation.
Option C: Option C is incorrect: the crust impairs rather than enhances penetration, so the issue is underdelivery to the mites, not overdosing.
Option E: Option E is incorrect: ivermectin alone is generally insufficient in crusted scabies; topical permethrin and keratolytic crust removal are needed alongside it.
4. Both malathion and spinosad remain effective against kdr-resistant head lice, but they reach that result through different molecular targets. Which comparison correctly states each agent's target?
A) Both inhibit acetylcholinesterase, so they are essentially the same drug under two names
B) Malathion inhibits acetylcholinesterase (causing acetylcholine to accumulate), whereas spinosad activates nicotinic acetylcholine receptors and glutamate-gated chloride channels; both targets lie off the sodium channel, which is why each escapes kdr resistance
C) Malathion activates glutamate-gated chloride channels, whereas spinosad inhibits acetylcholinesterase
D) Both activate the same nicotinic receptor, differing only in potency
E) Both prolong sodium-channel opening, like the pyrethroids, but with stronger binding
ANSWER: B
Rationale:
The integrative point is that two different off-channel targets both bypass kdr. Malathion is an organophosphate that inhibits acetylcholinesterase, so acetylcholine accumulates and overstimulates the louse nervous system. Spinosad activates nicotinic acetylcholine receptors and glutamate-gated chloride channels, producing neuromuscular hyperexcitation and paralysis. Neither acts on the voltage-gated sodium channel, so the kdr mutation does not protect against either, even though their mechanisms differ from each other.
Option A: Option A is incorrect: only malathion inhibits acetylcholinesterase; spinosad acts on receptors and chloride channels, so they are not the same drug.
Option C: Option C is incorrect: the targets are reversed here; malathion is the acetylcholinesterase inhibitor and spinosad is the receptor/chloride-channel activator.
Option D: Option D is incorrect: the two do not share the same nicotinic target differing only in potency; malathion acts on the enzyme acetylcholinesterase, not on nicotinic receptors.
Option E: Option E is incorrect: neither agent prolongs sodium-channel opening; that is the pyrethroid mechanism, and acting there would make them vulnerable to kdr.
5. A patient with advanced HIV (human immunodeficiency virus) infection and possible HIV encephalopathy is taking ritonavir and now needs ivermectin. Integrating ivermectin's central nervous system safety mechanism with this patient's circumstances, why is caution warranted?
A) Ritonavir destroys ivermectin in the stomach, so the drug will simply be ineffective
B) Ivermectin and ritonavir cannot be given within the same month for unrelated reasons
C) Ivermectin is normally unsafe in everyone, and HIV is irrelevant to the risk
D) Ritonavir increases ivermectin absorption from the gut, raising plasma levels but not brain levels
E) Ivermectin is normally kept out of the brain by the P-glycoprotein efflux pump at the blood-brain barrier; ritonavir inhibits P-glycoprotein and HIV encephalopathy may compromise the barrier, so both factors converge to raise ivermectin's central nervous system penetration and the risk of neurotoxicity
ANSWER: E
Rationale:
Two risk factors stack in this patient. Ivermectin is ordinarily excluded from the central nervous system (CNS) by P-glycoprotein (P-gp), an efflux pump at the blood-brain barrier (BBB). Ritonavir is a potent P-gp inhibitor, which lowers that protective efflux, and HIV encephalopathy can compromise BBB integrity itself. The integration of a P-gp inhibitor plus a potentially leaky barrier converges to increase ivermectin's CNS penetration and the risk of neurotoxicity, which is why caution and reassessment are warranted.
Option A: Option A is incorrect: the concern is increased CNS penetration and toxicity, not gastric destruction of the drug rendering it ineffective.
Option B: Option B is incorrect: there is no blanket one-month separation rule; the issue is a specific pharmacologic interaction at the blood-brain barrier.
Option C: Option C is incorrect: ivermectin is normally CNS-safe in people with an intact, P-gp-protected barrier; the HIV-related factors are precisely what change the risk here.
Option D: Option D is incorrect: the danger is greater brain penetration via reduced P-gp efflux and a compromised barrier, not merely higher plasma levels with the brain spared.
6. Across this module, several antiparasitic agents share a need for periodic complete blood count (CBC) monitoring because each can suppress the bone marrow. Which grouping correctly identifies agents that share this marrow-suppression concern?
A) Pyrimethamine (which inhibits dihydrofolate reductase in human marrow precursors), benznidazole (which causes leukopenia as a dose-limiting toxicity), and prolonged albendazole (which can cause leukopenia and thrombocytopenia in a minority) all warrant CBC monitoring
B) Permethrin, benzyl alcohol, and spinosad, because all topical lice agents suppress the marrow
C) Quinine, halofantrine, and artemether-lumefantrine, because all QTc-prolonging drugs suppress the marrow
D) Praziquantel, rifampicin, and corticosteroids, because all CYP3A4-related drugs suppress the marrow
E) Benzyl benzoate, crotamiton, and lindane, because all scabicides suppress the marrow
ANSWER: A
Rationale:
The unifying theme is bone marrow suppression and the CBC monitoring it requires. Pyrimethamine inhibits dihydrofolate reductase (DHFR) in human bone marrow precursors, causing megaloblastic anemia, leukopenia, and thrombocytopenia (folinic acid is given to prevent this). Benznidazole causes leukopenia as one of its dose-limiting toxicities. Prolonged albendazole can cause leukopenia and thrombocytopenia in a minority of patients. Recognizing this shared toxicity across otherwise unrelated drug classes is the integrative skill being tested.
Option B: Option B is incorrect: topical lice agents (permethrin, benzyl alcohol, spinosad) act locally with minimal systemic absorption and are not marrow suppressants.
Option C: Option C is incorrect: quinine, halofantrine, and artemether-lumefantrine are grouped by QTc prolongation, not by bone marrow suppression.
Option D: Option D is incorrect: praziquantel, rifampicin, and corticosteroids are linked through CYP3A4 metabolism interactions, not by suppressing the marrow.
Option E: Option E is incorrect: benzyl benzoate, crotamiton, and lindane are topical scabicides whose concerns are irritation and (for lindane) neurotoxicity, not marrow suppression.
7. Two patients present after heavy pyrethroid exposure. One has fine tremors, incoordination, and exaggerated startle; the other has writhing involuntary movements (choreoathetosis) and heavy salivation. Integrating structure with toxidrome, what distinguishes the two pyrethroid subclasses responsible?
A) The first patient was exposed to an organophosphate and the second to a pyrethroid; they are unrelated classes
B) Both pictures come from the same compound and reflect only the dose, with no structural basis
C) The tremor picture is caused by a Type I pyrethroid (no alpha-cyano group, such as permethrin), while the choreoathetosis-and-salivation picture is caused by a Type II pyrethroid (alpha-cyano group, such as deltamethrin or cypermethrin); the alpha-cyano substituent is the structural feature that shifts the toxidrome
D) The first patient was exposed to a Type II compound and the second to a Type I compound
E) Both toxidromes are caused by GABA-A receptor blockade, identical to lindane poisoning
ANSWER: C
Rationale:
The two syndromes map onto the two pyrethroid subclasses defined by a single structural feature. Type I pyrethroids lack the alpha-cyano group (permethrin) and produce repetitive firing manifesting as fine tremors, incoordination, and hypersensitivity to stimuli. Type II pyrethroids carry an alpha-cyano substituent (deltamethrin, cypermethrin, lambda-cyhalothrin) and produce persistent depolarization manifesting as choreoathetosis and hypersalivation. Linking the alpha-cyano group to the choreoathetosis-salivation picture is the integrative point.
Option A: Option A is incorrect: both pictures are pyrethroid toxidromes; the cholinergic features of organophosphate poisoning (miosis, bronchorrhea, bradycardia) are not what is described.
Option B: Option B is incorrect: the difference is not dose alone; it tracks the alpha-cyano structural distinction between Type I and Type II compounds.
Option D: Option D is incorrect: the assignment is reversed; tremor is the Type I picture and choreoathetosis-salivation is the Type II picture.
Option E: Option E is incorrect: pyrethroids act on sodium channels, not by GABA-A blockade; GABA-A antagonism is the lindane mechanism.
8. A pregnant woman in a high-transmission region has schistosomiasis. Applying the principle that guides antiparasitic prescribing in pregnancy, what is the correct reasoning about treating her?
A) All antiparasitic drugs are withheld in pregnancy by default, so she should not be treated until after delivery
B) Treatment decisions weigh the risk of the untreated infection against the drug's risk; because untreated schistosomiasis carries high morbidity and praziquantel has a reassuring safety record, praziquantel is recommended in pregnancy, including in high-transmission settings
C) She should be given diethylcarbamazine, which is the preferred agent for schistosomiasis in pregnancy
D) She should be given lindane, because its central nervous system absorption is beneficial in pregnancy
E) Praziquantel is absolutely contraindicated in pregnancy under all circumstances
ANSWER: B
Rationale:
The governing principle is a risk-benefit balance: the harm of the untreated infection is weighed against the pharmacologic risk of the drug. Untreated schistosomiasis carries substantial maternal and fetal morbidity, and praziquantel has a reassuring safety profile, so guidelines recommend treating schistosomiasis in pregnancy, including the first trimester in high-transmission settings, rather than withholding therapy. Applying this balance to the specific infection and drug is the conceptual task.
Option A: Option A is incorrect: antiparasitics are not uniformly withheld in pregnancy; when the untreated infection is more dangerous than the drug, treatment is given.
Option C: Option C is incorrect: diethylcarbamazine (DEC) is for lymphatic filariasis and is contraindicated in pregnancy; it is not a schistosomiasis treatment.
Option D: Option D is incorrect: lindane is contraindicated in pregnancy precisely because of central nervous system absorption and neurotoxicity, which is harmful, not beneficial.
Option E: Option E is incorrect: praziquantel is not contraindicated in pregnancy; it is recommended for schistosomiasis when the infection warrants treatment.
9. Before combining antimalarials, a clinician screens for additive cardiac risk. Which grouping correctly identifies antiparasitic agents that share QTc-interval prolongation as the key shared hazard, such that stacking them is dangerous?
A) Albendazole, mebendazole, and pyrantel, because all benzimidazole-class drugs prolong the QTc
B) Permethrin, malathion, and spinosad, because all ectoparasiticides prolong the QTc
C) Pyrimethamine, benznidazole, and prolonged albendazole, because all marrow suppressants prolong the QTc
D) Praziquantel, rifampicin, and metronidazole, because all CYP-interacting drugs prolong the QTc
E) Halofantrine (especially after mefloquine), quinine, and artemether-lumefantrine, because each prolongs the QTc interval, so combining them carries additive risk of torsades de pointes
ANSWER: E
Rationale:
The shared hazard linking these agents is QTc-interval prolongation. Halofantrine markedly prolongs the QTc and is especially dangerous after mefloquine; quinine (and quinidine) cause dose-dependent QTc prolongation; and artemether-lumefantrine also prolongs the QTc and should not be combined with other QTc-prolonging agents. Recognizing that these otherwise different antimalarials converge on the same cardiac risk, so that stacking them invites torsades de pointes, is the integrative point.
Option A: Option A is incorrect: the benzimidazoles (albendazole, mebendazole) and pyrantel are not characterized by QTc prolongation; albendazole's concerns are hepatic and hematologic.
Option B: Option B is incorrect: topical ectoparasiticides act locally with minimal systemic absorption and are not QTc-prolonging agents.
Option C: Option C is incorrect: pyrimethamine, benznidazole, and prolonged albendazole are grouped by marrow suppression, not QTc prolongation.
Option D: Option D is incorrect: praziquantel, rifampicin, and metronidazole are linked by cytochrome P450 metabolic interactions, not by prolonging the QTc.
10. Two different co-medications can each lower the effectiveness of praziquantel, but by distinct mechanisms acting in different compartments. Integrating both, which statement correctly distinguishes them?
A) Both rifampicin and corticosteroids lower praziquantel by inducing CYP3A4, so the mechanisms are identical
B) Rifampicin raises praziquantel plasma levels while corticosteroids raise its cerebrospinal fluid levels, so both increase efficacy
C) Rifampicin reduces praziquantel cerebrospinal fluid penetration while corticosteroids induce its hepatic metabolism, lowering plasma levels
D) Rifampicin induces CYP3A4 and accelerates praziquantel's hepatic metabolism, cutting plasma levels by about 85 percent, whereas corticosteroids reduce praziquantel's penetration into the cerebrospinal fluid by roughly 50 percent; one acts on systemic metabolism and the other on central nervous system delivery
E) Neither rifampicin nor corticosteroids has any effect on praziquantel
ANSWER: D
Rationale:
The two interactions lower praziquantel exposure in different ways and compartments. Rifampicin is a potent CYP3A4 inducer that speeds praziquantel's hepatic metabolism, dropping plasma levels by about 85 percent (so the combination is avoided). Corticosteroids, often needed in neurocysticercosis, reduce praziquantel penetration into the cerebrospinal fluid (CSF) by roughly 50 percent, lowering drug exposure at the central nervous system parasites. Distinguishing a systemic-metabolism effect from a CNS-delivery effect is the integrative skill.
Option A: Option A is incorrect: only rifampicin induces CYP3A4; corticosteroids act by reducing CSF penetration, so the mechanisms are not identical.
Option B: Option B is incorrect: both interactions reduce, not raise, praziquantel exposure, and they decrease rather than increase efficacy.
Option C: Option C is incorrect: the mechanisms are reversed here; rifampicin induces hepatic metabolism and corticosteroids reduce CSF penetration, not the other way around.
Option E: Option E is incorrect: both agents do affect praziquantel; rifampicin lowers plasma levels and corticosteroids lower CSF levels.
11. Several antiparasitic agents require liver function test (LFT) monitoring because of hepatotoxicity risk. Integrating across drug classes, which grouping correctly identifies agents that share clinically important hepatotoxicity warranting LFT surveillance?
A) Permethrin, benzyl alcohol, and crotamiton, because topical scabicides are hepatotoxic
B) Prolonged albendazole (transaminase elevation in 10 to 17 percent), benznidazole (hepatotoxicity as a dose-limiting toxicity), and the antimonials used for leishmaniasis (meglumine antimoniate, sodium stibogluconate), which carry significant hepatotoxicity risk
C) Spinosad, malathion, and pyrethrins, because all lice agents are hepatotoxic
D) Quinine, halofantrine, and mefloquine, because all are hepatotoxic rather than cardiotoxic or neurotoxic
E) Benzyl benzoate, lindane, and ivermectin, because all cause cirrhosis with short-term use
ANSWER: B
Rationale:
The integrative theme is hepatotoxicity and the LFT monitoring it demands. Prolonged albendazole raises transaminases in roughly 10 to 17 percent of patients; benznidazole lists hepatotoxicity among its dose-limiting toxicities; and the pentavalent antimonials (meglumine antimoniate, sodium stibogluconate) used for leishmaniasis carry significant hepatotoxicity risk requiring LFT monitoring throughout treatment. Grouping these three across unrelated classes by their shared hepatic risk is the conceptual task.
Option A: Option A is incorrect: topical scabicides (permethrin, benzyl alcohol, crotamiton) have minimal systemic absorption and are not notable hepatotoxins.
Option C: Option C is incorrect: topical lice agents (spinosad, malathion, pyrethrins) are not characterized by hepatotoxicity.
Option D: Option D is incorrect: quinine, halofantrine, and mefloquine are grouped by cardiac (QTc) and neuropsychiatric effects, not principally by hepatotoxicity.
Option E: Option E is incorrect: benzyl benzoate, lindane, and ivermectin do not cause cirrhosis with short-term use; lindane's concern is neurotoxicity, not hepatic fibrosis.
12. A clinician must choose a scabies agent for each of two children: one weighs 10 kg and the other weighs 20 kg. Integrating the weight-based safety cutoffs with the underlying reason for them, what is the correct selection logic?
A) For the 10-kg child, use topical permethrin 5% cream, because oral ivermectin is generally reserved for children of at least 15 kg (the more permeable blood-brain barrier in smaller infants raises central nervous system safety concerns); for the 20-kg child, oral ivermectin is an acceptable option since the child is above the 15-kg threshold
B) Both children should receive oral ivermectin at the adult dose, since weight is irrelevant to ivermectin safety
C) Both children should receive lindane, which is preferred in small children
D) The 10-kg child should receive oral ivermectin and the 20-kg child topical permethrin, reversing the usual thresholds
E) Neither child can be treated until reaching adult weight
ANSWER: A
Rationale:
The selection follows the 15-kg ivermectin threshold and its rationale. Oral ivermectin is generally reserved for children weighing at least 15 kg (about 2 years), because smaller infants have a more permeable blood-brain barrier and limited data raise central nervous system safety concerns. So the 10-kg child should receive topical permethrin 5% cream (low systemic absorption, preferred below 15 kg), while the 20-kg child, being above the threshold, may receive oral ivermectin. Matching each child to the agent by weight and the reason behind the cutoff is the integrative point.
Option B: Option B is incorrect: weight is not irrelevant; ivermectin is restricted below 15 kg, and an adult dose would be inappropriate for a 10-kg child.
Option C: Option C is incorrect: lindane is contraindicated in all children because of central nervous system neurotoxicity, so it is not preferred for either child.
Option D: Option D is incorrect: this reverses the correct thresholds; the smaller child should get topical permethrin and the larger child may get ivermectin, not the other way around.
Option E: Option E is incorrect: both children can be treated now with weight-appropriate agents; waiting until adult weight is unnecessary and wrong.
13. A frustrated prescriber suggests simply doubling the permethrin concentration to overcome kdr-resistant lice. Integrating the nature of target-site resistance, why does raising the dose fail here, and how does this differ conceptually from a metabolic form of resistance?
A) Raising the dose works fine; kdr resistance is always overcome by a higher concentration
B) kdr is a metabolic resistance, so a higher dose saturates the enzyme and restores efficacy
C) Doubling the dose fails because permethrin is not absorbed, not because of any resistance mechanism
D) kdr is a target-site mutation that lowers permethrin binding affinity at the sodium channel itself, so more drug still binds poorly to an altered target and a higher dose does not restore efficacy; this contrasts with metabolic resistance (faster enzymatic drug breakdown), where, in principle, overwhelming the enzyme could matter, whereas a changed binding site cannot be overcome by concentration alone
E) kdr can be reversed by giving permethrin together with an antihistamine, regardless of dose
ANSWER: D
Rationale:
kdr is a target-site resistance: a point mutation changes the sodium-channel binding site so that permethrin binds with reduced affinity. Because the defect is in how the drug fits its target, adding more drug still leaves it binding poorly to an altered channel, so dose escalation does not restore efficacy and cross-resistance extends to the whole pyrethroid class. This is conceptually different from metabolic resistance, where the parasite destroys the drug faster; the two resistance types call for different reasoning, and target-site resistance specifically defeats the dose-escalation strategy. The correct response is to switch to an off-channel agent.
Option A: Option A is incorrect: a higher dose does not overcome kdr, because the binding site itself is altered.
Option B: Option B is incorrect: kdr is a target-site mutation, not a metabolic one, so the saturate-the-enzyme logic does not apply.
Option C: Option C is incorrect: permethrin is absorbed adequately to act topically; the failure is due to target-site resistance, not lack of absorption.
Option E: Option E is incorrect: an antihistamine relieves itch but does not reverse kdr or kill lice, regardless of permethrin dose.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.